Journal of neurosurgery. Case lessons · 2025
Anaplastic lymphoma kinase-positive primary CNS anaplastic large cell lymphoma in a pediatric patient: illustrative case.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dolen Burak Duygu, Gulsever Cafer Ikbal, Poyraz Alperen, Unverengil Gokcen, Yegen Gulcin, Erbas Gulcan, Unal Tugrul Cem, Sencer Altay
Аннотация
BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive primary CNS anaplastic large cell lymphoma (ALCL) is an extremely rare pediatric malignancy. Its radiological appearance often mimics infectious or glial lesions, complicating diagnosis and delaying treatment.
OBSERVATIONS: The authors report the case of a 10-year-old immunocompetent female who presented with absence seizures and vomiting. Brain MRI revealed a left frontal lesion with peripheral contrast enhancement and diffusion restriction, suggestive of a cerebral abscess. She was started on antibiotics and underwent resection. Histopathology confirmed ALK-positive primary CNS ALCL. The patient was treated with NHL-BFM (non-Hodgkin lymphoma-Berlin-Frankfurt-Münster) chemotherapy, the ALK inhibitor lorlatinib, and focal cranial radiotherapy (18 Gy/22 fractions). She remains in complete remission at 18 months. A systematic review of 15 pediatric ALK-positive CNS ALCL cases revealed male predominance, supratentorial location, and inconsistent treatment protocols. Methotrexate-based chemotherapy was most common treatment; the role of radiotherapy and surgery varied.
LESSONS: ALK-positive primary CNS ALCL should be considered in the differential diagnosis of pediatric intracranial masses with atypical imaging. Early histological confirmation is essential. While chemotherapy remains central to treatment, targeted therapies and radiation-sparing approaches require further investigation to improve outcomes and reduce long-term morbidity in children. https://thejns.org/doi/10.3171/CASE25522.
OBSERVATIONS: The authors report the case of a 10-year-old immunocompetent female who presented with absence seizures and vomiting. Brain MRI revealed a left frontal lesion with peripheral contrast enhancement and diffusion restriction, suggestive of a cerebral abscess. She was started on antibiotics and underwent resection. Histopathology confirmed ALK-positive primary CNS ALCL. The patient was treated with NHL-BFM (non-Hodgkin lymphoma-Berlin-Frankfurt-Münster) chemotherapy, the ALK inhibitor lorlatinib, and focal cranial radiotherapy (18 Gy/22 fractions). She remains in complete remission at 18 months. A systematic review of 15 pediatric ALK-positive CNS ALCL cases revealed male predominance, supratentorial location, and inconsistent treatment protocols. Methotrexate-based chemotherapy was most common treatment; the role of radiotherapy and surgery varied.
LESSONS: ALK-positive primary CNS ALCL should be considered in the differential diagnosis of pediatric intracranial masses with atypical imaging. Early histological confirmation is essential. While chemotherapy remains central to treatment, targeted therapies and radiation-sparing approaches require further investigation to improve outcomes and reduce long-term morbidity in children. https://thejns.org/doi/10.3171/CASE25522.